JP7304944B2 - 腎線維症又は腎疾患の予防又は治療におけるアクタリットの使用 - Google Patents

腎線維症又は腎疾患の予防又は治療におけるアクタリットの使用 Download PDF

Info

Publication number
JP7304944B2
JP7304944B2 JP2021522114A JP2021522114A JP7304944B2 JP 7304944 B2 JP7304944 B2 JP 7304944B2 JP 2021522114 A JP2021522114 A JP 2021522114A JP 2021522114 A JP2021522114 A JP 2021522114A JP 7304944 B2 JP7304944 B2 JP 7304944B2
Authority
JP
Japan
Prior art keywords
subject
amount
repirinast
renal
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529829A (ja
JPWO2020000092A5 (enExample
Inventor
マーク・ウィリアムズ
Original Assignee
アルジャーノン・ファーマスーティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルジャーノン・ファーマスーティカルズ・インコーポレイテッド filed Critical アルジャーノン・ファーマスーティカルズ・インコーポレイテッド
Publication of JP2021529829A publication Critical patent/JP2021529829A/ja
Publication of JPWO2020000092A5 publication Critical patent/JPWO2020000092A5/ja
Application granted granted Critical
Publication of JP7304944B2 publication Critical patent/JP7304944B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021522114A 2018-06-27 2019-06-25 腎線維症又は腎疾患の予防又は治療におけるアクタリットの使用 Active JP7304944B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690738P 2018-06-27 2018-06-27
US62/690,738 2018-06-27
US201962809330P 2019-02-22 2019-02-22
US62/809,330 2019-02-22
PCT/CA2019/050881 WO2020000092A1 (en) 2018-06-27 2019-06-25 The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease

Publications (3)

Publication Number Publication Date
JP2021529829A JP2021529829A (ja) 2021-11-04
JPWO2020000092A5 JPWO2020000092A5 (enExample) 2022-07-06
JP7304944B2 true JP7304944B2 (ja) 2023-07-07

Family

ID=68985352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522114A Active JP7304944B2 (ja) 2018-06-27 2019-06-25 腎線維症又は腎疾患の予防又は治療におけるアクタリットの使用

Country Status (6)

Country Link
US (1) US12280026B2 (enExample)
EP (2) EP3813817A4 (enExample)
JP (1) JP7304944B2 (enExample)
CN (1) CN112423742B (enExample)
CA (1) CA3105127A1 (enExample)
WO (1) WO2020000092A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3920921A4 (en) * 2019-02-07 2022-11-02 Alsatech, Inc. POLYVALENT EMOXYPIN DERIVATIVES
WO2020191503A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
WO2020191501A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
WO2020191502A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Use of emoxypine and derivatives thereof for treating kidney disorders and inflammatory bowel disease
CN113368106B (zh) * 2020-02-25 2023-09-29 渐宽(苏州)生物科技有限公司 艾托莫德用于防治特发性肺纤维化的药物中的用途
IT202100014177A1 (it) * 2021-05-31 2022-12-01 Sunnutrapharma S R L Utilizzo della istradefillina per ridurre la fibrosi d’organo
WO2025040956A2 (en) * 2023-08-09 2025-02-27 Rautiola Davin Drug to treat stimulant addiction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089345A (ja) 2003-09-16 2005-04-07 Tendou Seiyaku Kk 虫刺され治療薬
JP2008528627A (ja) 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． グルクロン酸化されたネビボロール代謝産物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1601978C (ru) * 1988-12-29 1995-10-27 Научно-исследовательский институт фармакологии РАМН Способ получения n-(4-бромфенил)-n-(2-адамантил)амина
RU2109727C1 (ru) * 1994-06-10 1998-04-27 Научно-исследовательский институт фармакологии РАМН Способ получения адамантан-2-она
KR100535305B1 (ko) * 2001-04-16 2005-12-08 다이호야쿠힌고교 가부시키가이샤 토실산 스프라타스트 결정
US7838552B2 (en) * 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
JP4794148B2 (ja) * 2004-09-10 2011-10-19 大鵬薬品工業株式会社 ネフローゼ症候群治療剤
EP1942909A4 (en) * 2005-10-04 2010-01-06 Nitromed Inc METHODS OF TREATING RESPIRATORY DISORDERS
WO2008078826A1 (ja) * 2006-12-26 2008-07-03 Taiho Pharmaceutical Co., Ltd. 糖尿病性ニューロパチー治療剤
ES2689132T3 (es) * 2011-09-29 2018-11-08 Ono Pharmaceutical Co., Ltd. Derivado de fenilo
KR20160058886A (ko) * 2013-10-03 2016-05-25 밀레니엄 파머슈티컬스 인코퍼레이티드 전신 홍반성 낭창 및/또는 낭창성 신염의 예방 또는 치료 방법
WO2017032384A1 (en) * 2015-08-25 2017-03-02 Conrig Pharma Aps Compound and use in the treatment of cough
WO2017108041A1 (en) * 2015-12-23 2017-06-29 Conrig Pharma Aps Suplatast tosilate for treating cough associated with interstitial lung disease
US20210237925A1 (en) 2018-04-20 2021-08-05 Tetra Laval Holdings & Finance S.A. A sealed package containing a pourable food product and a sheet packaging material for producing a sealed package containing a pourable food product

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089345A (ja) 2003-09-16 2005-04-07 Tendou Seiyaku Kk 虫刺され治療薬
JP2008528627A (ja) 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． グルクロン酸化されたネビボロール代謝産物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Toxicology，2011年，Vol. 279, No.1-3，91-99
医薬品研究，1986年，Vol.17, No.3，545-559

Also Published As

Publication number Publication date
EP3813817A1 (en) 2021-05-05
JP2021529829A (ja) 2021-11-04
US12280026B2 (en) 2025-04-22
CN112423742A (zh) 2021-02-26
CN112423742B (zh) 2024-03-19
US20210260000A1 (en) 2021-08-26
EP4046633A1 (en) 2022-08-24
WO2020000092A1 (en) 2020-01-02
CA3105127A1 (en) 2020-01-02
EP3813817A4 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
JP7304944B2 (ja) 腎線維症又は腎疾患の予防又は治療におけるアクタリットの使用
JP4884588B2 (ja) １−［４−（５−シアノインドール−３−イル）ブチル］−４−（２−カルバモイル−ベンゾフラン−５−イル）−ピペラジンおよびこの生理学的に受け入れられる塩の新規な使用
TWI539950B (zh) 用於預防或治療貓之全身性疾病之血管緊張素ii受體拮抗劑
KR20170122777A (ko) 트라디피턴트에 의한 치료 방법
CN112654357B (zh) 用于治疗非酒精性脂肪性肝炎的组合物和方法
JP2010514696A (ja) 心血管症状の低減
JP2014520856A (ja) 併用ａｌｓ療法
JP2005516977A (ja) 尿失禁の処置での４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ（２，３−ｄ−ピリミジン）の使用
CN111712241B (zh) σ-1受体激动剂收缩期血压疗法
EP3851103A1 (en) Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound
JP6934859B2 (ja) 腎疾患の治療のための医薬
KR20230061527A (ko) 염증성 장 질환을 치료하는 방법
WO2005070406A1 (en) Combination of organic compounds
KR20070074576A (ko) 사구체 질환 치료제
JP2004500333A (ja) 胃腸管障害の治療における、２−アミノ−４−（４−フルオロナフタ−１−イル）−６−イソプロピルピリミジンの使用
WO2020191503A1 (en) Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
WO2021102330A1 (en) Compositions and methods for treatment of pain
HK40047721A (en) Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound
JP2007326824A (ja) 滑膜細胞増殖抑制剤、並びにこれを利用した薬用組成物及び治療方法
EP1778248A1 (en) A composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
EP3996709A1 (en) Telmisartan for the treatment of hypertension in dogs
HK1259806A1 (en) Medicine for treating renal disease
HK1111616A (en) Therapeutic agent for glomerular disease
WO2003101437A2 (en) Method of treating asthma using fexofenadine
JP2013508372A (ja) 多発性硬化症を治療するためのテリフルノミド及び酢酸ガラティラメルを組み合わせた使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230627

R150 Certificate of patent or registration of utility model

Ref document number: 7304944

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150